BullBD Old Apps Site
Home
Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

RENATA

All Eps Dividend Board Agm Q1 Q2 Q3

RENATA 14-Nov-2019

With reference to their earlier news disseminated by DSE on 30.10.2019 the Company has further informed that the Board of Directors of the Company has approved the following business i) Considered the proposal of merger of Renata Limited (Transferee Company) with its subsidiary Renata Oncology Limited (Transferor Company) based on the draft Scheme of Amalgamation placed before the Board ("Scheme") with July 1, 2019 as the appointed date, (cont. 1)

RENATA 14-Nov-2019

(Q1 Un-audited): Consolidated EPS was Tk. 12.78 for July-September 2019 as against Tk. 10.46 for July-September 2018; Consolidated NOCFPS was Tk. 19.16 for July-September 2019 as against Tk. 19.07 for July-September 2018. Consolidated NAV per share was Tk. 243.58 as on September 30, 2019 and Tk. 230.90 as on June 30, 2019.

RENATA 06-Nov-2019

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 13, 2019 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2019.

RENATA 30-Oct-2019

There will be no price limit on the trading of the shares of the Company today (30.10.2019) following its corporate declaration.

RENATA 30-Oct-2019

(Continuation news of RENATA): iii) Bonus shares is not declared from capital reserve or revaluation reserve or any unrealized gain or out of profit the earned prior to incorporation of the Company or through reducing paid up capital or through doing anything so that the post-dividend retained earning become negative or a debit balance. (end)

RENATA 30-Oct-2019

(Continuation news of RENATA): The Company has also informed that i) The bonus shares has been recommended in view to utilize its retained amount as capital for manufacturing facility expansion. ii) Bonus shares is declared out of accumulated profit. (cont.4)

RENATA 30-Oct-2019

(Continuation news of RENATA): Venue: Corporate Headquarters Premises, Plot No. 1, Milk Vita Road, Section-7, Mirpur, Dhaka. Record Date for AGM & EGM: 20.11.2019. The Company has also reported Consolidated EPS of Tk. 46.63, Consolidated NAV per share of Tk. 230.90 and Consolidated NOCFPS of Tk. 52.54 for the year ended on June 30, 2019 as against Tk. 38.57, Tk. 192.56 and Tk. 32.93 respectively for the same period of the previous year. (cont.3)

RENATA 30-Oct-2019

(Continuation news of RENATA): They also informed that Renata Oncology Limited and Renata Limited will be merged under the provision of Section 228 & 229 of the Companies Act, 1994 subject to the consent of Shareholders and approval from the Honorable High Court division of Supreme Court of Bangladesh. Date of AGM & EGM: 21.12.2019, Time for AGM & EGM: 11:00:00 AM, & 12:30 PM respectively, (cont.2)

RENATA 30-Oct-2019

The Board of Directors has recommended 100% cash and 10% stock dividend for the year ended on June 30, 2019. The Board has also decided to increase its Authorized Capital of the Company from Tk. 1,000,000,000 to Tk. 2,500,000,000 as well as amendment of Clause V and 5 of Memorandum and Articles of Association. (cont.1)

RENATA 21-Oct-2019

As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 29, 2019 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2019.

Previous Next page